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Interferon-g (IFN-g) is an important mediator of immunity and inflammation that utilizes the JAK-STAT
signaling pathway to activate the STAT1 transcription factor. Many functions of IFN-g have been ascribed
to direct STAT1-mediated induction of immune effector genes, but recently it has become clear that key
IFN-g functions are mediated by cross-regulation of cellular responses to other cytokines and inflammatory
factors. Here, we review mechanisms by which IFN-g and STAT1 regulate signaling by Toll-like receptors,
inflammatory factors, tissue-destructive cytokines, anti-inflammatory cytokines, and cytokines that activate
opposing STATs. These signaling mechanisms reveal insights about how IFN-g regulates macrophage acti-
vation, inflammation, tissue remodeling, and helper and regulatory T cell differentiation and how Th1 and
Th17 cell responses are integrated in autoimmune diseases.Introduction
Since the first description of a type II interferon (IFN) activitymore
than three decades ago, much has been learned about the
biological effects and signal transduction mechanisms of the
sole type II IFN, IFN-g. IFN-g is one of themost important endog-
enous mediators of immunity and inflammation. IFN-g plays
a key role in macrophage activation, inflammation, host defense
against intracellular pathogens, T helper 1 (Th1) cell responses,
and tumor surveillance and immunoediting. In parallel, IFN-g
exerts regulatory functions to limit tissue damage associated
with inflammation and to modulate Th and regulatory T (Treg)
cell differentiation. IFN-g can either augment or suppress
autoimmunity and the associated pathology in a context- and
disease-specific manner.
IFN-g signals mainly through the Janus kinase (JAK)-signal
transducer and activator of transcription (STAT) intracellular
signal transduction pathway to achieve transcriptional activation
of IFN-g-inducible genes. The STAT family of transcription
factors consists of seven members, all of which are involved in
receptor signaling by various cytokines and growth factors. The
major STAT protein activated by IFN-g is STAT1. Many IFN-g
functions are mediated by direct activation of immune effector
genes by STAT1, including genes encoding antiviral proteins,
microbicidal molecules, phagocytic receptors, chemokines,
cytokines, and antigen-presenting molecules. Canonical Jak-
STAT signalingmechanisms leading to activation of well-charac-
terized STAT1 target genes have been previously reviewed
(Stark, 2007) and will not be discussed here. A wide spectrum
of IFN-g activities cannot be explained on the basis of activation
and direct effector functions of STAT1 target genes. Activation of
other STATs and alternative signaling pathways can contribute to
IFN-g function in certain cell contexts (reviewed in van Boxel-
Dezaire and Stark, 2007 and Gough et al., 2008). Importantly,many key IFN-g functions are mediated by cross-regulation of
cellular responses to other cytokines and inflammatory factors.
The capacity of IFN-g to cross-regulate signaling pathways
induced by other endogenous and exogenous factors is less
appreciated, and the underlying mechanisms are more recently
described. The mechanisms and (patho)physiological impact of
IFN-g-mediated cross-regulation of signal transduction will be
the main focus of the current review.
IFN-g-Induced Jak-STAT1 Signaling
In canonical IFN-g-Jak-STAT1 signaling (recently reviewed in
Stark, 2007), ligand engagement of the IFN-g receptor leads to
activation of receptor-associated Jak1 and Jak2 and phosphor-
ylationof a receptor tyrosine residue (Y440) that servesasadock-
ing site for STAT1, which exists in a latent state in the cytoplasm.
STAT1 is then activated by phosphorylation of tyrosine 701,
translocates to the nucleus, binds to a regulatory DNA element
termed gamma-activated sequence (GAS), and stimulates
transcription of STAT1 target genes. STAT1 binds to DNA as a
dimer composed of two STAT1 subunits in a parallel configura-
tion, such that amino- and carboxy-termini are aligned (Figure 1).
Transcriptional activity of STAT1 is augmented by MAP kinase-
mediated phosphorylation of a serine residue in the carboxy-
terminal transcription activation domain, and the amplitude of
activation is fine tuned by feedback inhibition mediated by
various negative regulators of Jak-STAT signaling such as
SOCS1 (O’Shea and Murray, 2008). SOCS1 is a key suppressor
of IFN-g activities in vivo given that SOCS1 deficiency in mice
leads to neonatal lethality characterized by uncontrolled IFN-g
responses (Alexander et al., 1999; Marine et al., 1999). Recent
evidence has highlighted that STAT1 undergoes cycles of activa-
tion-inactivation that are coupledwith nuclear-cytoplasmic shut-
tling and regulated by posttranslational modifications, includingImmunity 31, October 16, 2009 ª2009 Elsevier Inc. 539
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Reviewdephosphorylation of tyrosine 701 and acetylation of lysine resi-
dues (Figure 1).
Inactivation of nuclear STAT1 occurs rapidly after binding to
chromatin and activation of target gene transcription. STAT1
dissociates from DNA and the STAT1 dimer undergoes a confor-
mational change, such that the parallel orientation of STAT1
monomers changes to an antiparallel configuration that exposes
phosphotyrosine residues and thus facilitates dephosphoryla-
tion of STAT1 by phosphatases (Mao et al., 2005; Mertens
et al., 2006; Zhong et al., 2005). Subsequently, STAT1 is dephos-
phorylated by phosphatases such as TCP45, and dephosphory-
lated STAT1 returns to the cytoplasm, in which it can potentially
serve as the substrate for subsequent rounds of activation and
inactivation (Figure 1). There is accumulating evidence that
cytoplasmic STATs do not exist predominantly as monomers
(Braunstein et al., 2003; Ota et al., 2004) but instead as
homodimers with the two STAT1 subunits in an antiparallel
configuration (Mao et al., 2005). In this model, STAT1 tyrosine
phosphorylation triggers or stabilizes a conformational change
of pre-existing STAT1 dimers from antiparallel to parallel config-
uration and results in increased abundance of parallel dimers
with an exposed nuclear localization sequence and high DNA-
binding activity (Wenta et al., 2008).
Figure 1. IFN-g-Induced STAT1 Activation Cycle Mediated by
Tyrosine Phosphorylation and Lysine Acetylation
Unphosphorylated STAT1 dimers are present in the cytoplasm in an equilib-
rium state between a parallel and antiparallel configuration of STAT1 subunits.
Upon activation of IFNGR signaling, STAT1 is phosphorylated by JAK kinases
on tyrosine 701 and phosphorylation stabilizes a parallel dimer configuration
that exhibits DNA binding activity. Phosphorylated STAT1 translocates to
nucleus, binds to GAS DNA sequences, and activates transcription of
STAT1 target genes. Active STAT1 in the nucleus undergoes acetylation on
lysines 410 and 413, a process catalyzed by histone acetyltransferases
(HATs) such as CBP. Acetylation flags STAT1 for dephosphorylation by the
STAT1 phosphatase TCP45; an antiparallel dimer configuration facilitates effi-
cient dephosphorylation and thus deactivation. Dephosphorylated STAT1
shuttles back to cytoplasm, where histone deacetylases (HDACs) such as
HDAC3 and possibly Sirtuins deacetylate STAT1 and complete the phosphor-
ylation-acetylation cycle. Deacetylation of STAT1 results in less efficient
TCP45-mediated dephosphorylation and thus licenses STAT1 for IFNGR-
JAK-mediated tyrosine phosphorylation.540 Immunity 31, October 16, 2009 ª2009 Elsevier Inc.The function of STATs and the transit of STAT1 through the
activation-inactivation cycle are regulated by lysine acetylation
(Kramer et al., 2006; Kramer et al., 2009; Nie et al., 2009; Tang
et al., 2007; Yuan et al., 2005). The acetylation status of several
STATs including STAT1, STAT2, andSTAT3 is dynamically deter-
minedbyopposing activities of histoneacetyltransferases (HATs)
versus histone deacetylases (HDACs). However, the impact of
STAT acetylation on signaling is not well understood, given that
both positive and negative roles of STAT acetylation on cytokine
receptor signaling have been reported. The preponderance of
evidence suggests that acetylation of STAT3 is often, although
not exclusively, associated with positive regulation of signal
transduction (Nie et al., 2009; Wang et al., 2005; Yuan et al.,
2005), whereas acetylation of STAT1 is associatedwith inhibitory
effects (Kramer et al., 2006; Kramer et al., 2009). STAT3 acetyla-
tion by the HAT CBP has been correlated with increased DNA-
binding and transactivation activity (Wang et al., 2005; Yuan
et al., 2005) and potentially with its anti-inflammatory properties
(Sun et al., 2009). Conversely, deacetylation of STAT3 by the
HDAC Sirtuin 1 correlates with decreased STAT3 tyrosine phos-
phorylation andactivity (Nie et al., 2009). Similar toSTAT3, STAT1
is also acetylated by CBP (Kramer et al., 2006; Kramer et al.,
2009). However, in contrast to STAT3, STAT1 acetylation seems
to play a negative role in signaling. It was recently reported that
acetylation of STAT1 on lysine residues 410 and 413 in the
nucleus results in enhanced interaction with TCP45 and
increased dephosphorylation (Kramer et al., 2009). Thus, acety-
lation ‘‘flags’’ STAT1 for inactivation. The mechanism by which
acetylation promotes interaction of STAT1 with TCP45 is not
clear. One possibility is that acetylation promotes a change to
the antiparallel configuration of STAT1 subunits that facilitates
dephosphorylation by TCP45. In this speculative model, acety-
lated cytoplasmic STAT1 is refractory to activation because of
associationwith TCP45. Deacetylation of STAT1 that ismediated
by HDACs such as HDAC3 (Kramer et al., 2009) thus promotes
increased tyrosine phosphorylation and stabilization of the
active parallel configuration STAT1 dimer (Figure 1). This require-
ment for HDAC activity for STAT1 activation could potentially
explain the paradoxical observation that HDAC inhibitors
suppress STAT1-dependent transcription (Chang et al., 2004;
Nusinzon and Horvath, 2003). This acetylation-mediated nega-
tive regulatory mechanism can potentially be bypassed by de
novo synthesis of STAT1, which is an important mechanism for
augmenting long-term STAT1 activity (Hu et al., 2002).
The role of acetylation in regulating the STAT1 activation cycle
opens new avenues for regulation and modulation of STAT1
function and crosstalk with heterologous signaling pathways.
For example, the activity of certain STAT HDACs, such as
Sirtuin1, is regulated by the overall cellular metabolic state as
reflected in the NAD/NADH ratio and can be selectively and ther-
apeutically modulated by small molecule compounds (Finkel
et al., 2009). Other, as yet unknown, mechanisms control the
translocation of HDACs and HATs to the cytoplasm where they
can modify STATs. Despite recent progress, many unanswered
questions remain regarding STAT acetylation. One outstanding
question is what underlies the differential functional outcomes
of acetylation of different STAT molecules. Plausible explana-
tions include different acetylation sites (lysines 410 and 413 of
STAT1 versus lysines 679, 685, 707, and 709 of STAT3) and
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ReviewFigure 2. IFN-g Signaling Disrupts TLR-
Induced Feedback Inhibitory Loops
As shown on the left, IFN-g enhances TLR-
induced TNF production by disrupting an IL-10-
mediated inhibitory loop. IFN-g signaling leads to
increased activity of GSK3, which negatively regu-
lates Il10 expression by suppressing activation of
transcription factors CREB and AP-1. As shown
on the right, IFN-g enhances TLR-induced IL-6
and IL-12 production by disrupting an inhibitory
loop mediated by canonical Notch target genes
Hes1 and Hey1. IFN-g signaling downregulates
intracellular NICD2 amounts and thus inhibits
expression of Hes1 and Hey1. Hes1 and Hey1
are transcription repressors that negatively regu-
late Il6 and Il12 gene expression.different structural changes induced by acetylation. Because
STAT1 and STAT3 often antagonize each other’s functions in
many processes including inflammation and tumorigenesis,
differential regulation of these STATs by acetylation may repre-
sent a mechanism to regulate the balance of STAT function
downstream of cytokine receptors.
Enhancement of Innate Immune Activation
It has been long appreciated that IFN-g promotes innate immune
responses by activating macrophages. One mechanism of IFN-
g-mediated macrophage activation is direct effector gene acti-
vation via STAT1 as discussed above. Another way for IFN-g
to achieve strong activation effects is by enhancing macrophage
responsiveness to other inflammatory stimuli, such as Toll-like
receptor (TLR) ligands, tumor necrosis factor (TNF), and type I
IFNs; this phenomenon is termed ‘‘priming.’’ IFN-g primes
macrophages for enhanced type I IFN responses characterized
by increased STAT1 activation (Hu et al., 2002). Conversely,
type I IFNs augment IFN-g signaling via association of type I
and type II IFN receptor subunits (Takaoka et al., 2000). Priming
of TLR responses by IFN-g greatly augments TLR-induced
expression of inflammatory mediators and immune effectors,
including multiple cytokines and chemokines, and profoundly
affects biological outcomes of innate immunity and inflamma-
tion. The mechanisms underlying IFN-g-mediated priming have
been the subject of extensive investigation, and it has been sug-
gested that IFN-g priming enhances TLR-activated signal trans-
duction. For example, IFN-g priming increases TLR expression,
promotes NF-kB activation, and induces transcription factors
that are essential for expression of certain TLR-responsive
genes. However, enhancement of TLR signaling can not explain
the full spectrum of activation achieved by IFN-g priming, given
that accumulating evidence suggests that inactivation of feed-
back inhibition pathways by IFN-g is important for the broad
and sustained activation of macrophage effector genes and
mechanisms that is characteristic of primed cells. Of note,
enhancement of positive signaling and inactivation of feedback
inhibition are two complementary mechanisms that reinforce
each other to achieve the robust priming effects seen with
IFN-g. The enhancement of positive TLR signaling by IFN-g has
been reviewed elsewhere (Schroder et al., 2006); herein wereview recent progress regarding IFN-g-mediated abrogation
of TLR-induced feedback inhibitory loops.
IL-10 is a major anti-inflammatory cytokine induced by TLR
signaling and functions to inhibit production of TLR-induced
proinflammatorymediators, such as TNF, in a STAT3-dependent
manner (Mosser and Zhang, 2008). IFN-g priming disrupts this
IL-10-STAT3 feedback inhibitory loopand thus leads to increased
production of inflammatory cytokines. One mechanism by
which IFN-g suppresses the IL-10-STAT3 axis involves inhibition
of TLR-induced Il10 gene expression. IFN-g suppresses IL-10
production by increasing the activity of glycogen synthase kinase
3b (GSK3b), a serine-threonine kinase that inhibits the function of
AP-1 and CREB, two transcription factors critical for Il10 expres-
sion. Upon activation of TLRs, GSK3b is phosphorylated and
inactivated by the PI3K-Akt signaling pathway, and inactivation
of GSK3b allows Il10 to be expressed. IFN-g priming overcomes
this TLR-induced inhibition of GSK3b and thus restores the
capacity of GSK3b to inhibit Il10 expression (Hu et al., 2006)
(Figure 2, left panel). IFN-g-GSK3b-mediated regulation of TLR
responses is best characterized with IL-10 as a target. However,
given that GSK3b controls the function of CREB and AP-1, key
transcription factors involved in expression ofmanyTLR-induced
genes, it is likely that IFN-g regulates expression of a subset of
TLR-inducible genes via GSK3 (Ho et al., 2008; Hu et al., 2007).
One unanswered question is the mechanism by which IFN-g
activates GSK3b. A potential mechanism is IFN-g-mediated
suppression of TLR-induced PI3K-Akt signaling, with resultant
decreased inhibitory phosphorylation of GSK3b (Hu et al.,
2006). However, the mechanism whereby IFN-g inhibits the
PI3K pathway is not clear. Alternatively, IFN-g can inactivate
GSK3 phosphatases or promote alternative GSK3 activation via
the tyrosine kinase Pyk2 (Tsai et al., 2009). As GSK3 is involved
in various signaling pathways including Wnt-b-catenin signaling,
IFN-g regulation of GSK3b has broader implications for signal
transduction crosstalk, such as potential cross-regulation
between IFN-g and Wnt pathways (Kockeritz et al., 2006).
In addition to inactivation of the IL-10-STAT3 axis, IFN-g
disrupts another feedback inhibitory loop involving Notch target
genes Hes1 and Hey1, which are transcriptional repressors (Hu
et al., 2008a). The Notch pathway, whose functions have been
predominantly characterized in developmental biology systems,Immunity 31, October 16, 2009 ª2009 Elsevier Inc. 541
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and to be regulated by IFN-g. In macrophages, expression of
canonical Notch target genes Hes1 and Hey1 is induced by
TLR stimulation. Expression of Notch target genes is synergisti-
cally activated by TLR and Notch pathways by cooperation
between RBP-J, a master transcription factor downstream of
Notch signaling, and the TLR signaling components IKKb and
p38. After induction by TLRs, transcription repressors Hes1
and Hey1 suppress TLR-induced IL-6 and IL-12 expression,
constituting another feedback inhibitory loop that dampens
cytokine production (Figure 2, right). IFN-g signaling inhibits
expression of Hes1 and Hey1 at least in part by downregulating
amounts of NICD2, the intracellular cleaved fragment of Notch2
receptor that binds RBP-J and activates Notch target gene
expression. Potential mechanisms by which IFN-g downregu-
lates NICD2 include modulation of proteases that generate and
degrade NICD2 and activation of GSK3 that destabilizes of
NICD proteins (Espinosa et al., 2003). Thus, IFN-g primes for
augmented TLR-induced IL-6 and IL-12 production by disrupt-
ing an inhibitory loop mediated by Hes1 and Hey1 (Hu et al.,
2008a). The above examples suggest that inactivation of feed-
back inhibitory pathways by IFN-g is a common mechanism of
priming, and additional examples are likely to be uncovered.
Another notion emerging from these studies is that IFN-g selec-
tively and differentially regulates expression of subsets of TLR
target genes by targeting distinct TLR-induced signaling mole-
cules such as AP-1 (Hu et al., 2007). This provides an additional
mechanism for selective regulation of TLR responses; the impor-
tance of such selective regulation has recently been highlighted
by Medzhitov and colleagues (Foster et al., 2007; Foster and
Medzhitov, 2009).
IFN-g also directly inhibits signaling pathways downstream of
anti-inflammatory cytokines to antagonize their suppressive
functions. IFN-g antagonizes anti-inflammatory effects of IL-10
both by attenuating IL-10 production, as discussed above, and
by suppressing IL-10 signaling. Anti-inflammatory action of
IL-10 is predominantly mediated by STAT3 and IFN-g cross-
regulates IL-10 signaling by abrogating expression of STAT3
target genes. IFN-g does not suppress upstream IL-10 signaling,
including activation of Jaks. Instead, IFN-g shifts the balance of
IL-10 STAT activation from STAT3 to STAT1, resulting in induc-
tion of STAT1 target genes by IL-10 (Herrero et al., 2003). Inhibi-
tion of IL-10-STAT3 signaling has important biological impact
because the anti-inflammatory activity of IL-10 is diminished
after IFN-g priming (Herrero et al., 2003). The mechanisms of
STAT1-STAT3 cross-regulation are discussed below. TGF-b is
another cytokine with important anti-inflammatory function that
is subject to the antagonistic action of IFN-g. IFN-g induces
expression of Smad7, an inhibitory Smad, and thus inhibits
TGF-b-induced activation of the activating Smad3 and of
TGFb-responsive genes (Ulloa et al., 1999). STAT1 also directly
binds Smad3 and inhibits its function (Ghosh et al., 2001). In
summary, inhibition of expression and function of anti-inflamma-
tory molecules represents an important mechanism of IFN-g-
mediated priming of enhanced innate immune responses.
Attenuation of Tissue Destruction
The activating effects of IFN-g on immunity and inflammation
have been extensively studied and are well established. At the542 Immunity 31, October 16, 2009 ª2009 Elsevier Inc.same time, IFN-g possesses crucial homeostatic functions that
limit inflammation-associated tissue damage. This enables the
host to utilize one mediator, IFN-g, to regulate the balance
between clearance of invading pathogens and limiting collateral
damage to the host. IFN-g plays an important role in limiting
tissue damage associated with acute infections and with chronic
inflammation in autoimmune diseases such as inflammatory
arthritis and experimental allergic encephalomyelitis (EAE).
Mechanisms underlying the homeostatic functions of IFN-g,
which include inhibition of gene expression, inhibition of migra-
tion and differentiation of tissue-destructive cells, and inhibition
of signaling by tissue-destructive cytokines, are reviewed in
this section.
One mechanism by which IFN-g attenuates tissue destruction
is inhibition of expression of genes that encode tissue-destruc-
tive factors, such as matrix metalloproteinases (MMPs), serine
proteases, coagulation factors, complement components, and
enzymes involved in prostaglandin metabolism (Barrios-Rodiles
and Chadee, 1998; Ho et al., 2008; Ma et al., 2001; Sanceau
et al., 2002; Zhou et al., 2003; L.B.I., unpublished data). IFN-g
broadly suppresses expression of multiple MMPs including
MMP1, MMP2, MMP3, MMP7, MMP9, and MMP10 induced
by various receptors such as TLRs and IL-1R. IFN-g-mediated
suppression of MMPs requires STAT1. However, to date there
is no compelling evidence that STAT1 directly suppresses gene
expression, including expression of genes that encode MMPs.
Instead, IFN-g inhibits receptors and signals that induce
MMP expression (Figure 3). IFN-g suppresses IL-1-induced
MMP expression in macrophages by STAT1-dependent down-
regulation of IL-1RI (Hu et al., 2005a). Inhibition at this proximal
step inactivates all signaling cascades downstream of the IL-1
receptor and results in a global block in macrophage responses
to IL-1 (Browning andRibolini, 1987; Dickensheets andDonnelly,
1997; Hu et al., 2005a). IFN-g-mediated inhibition of TLR-
induced genes targets downstream signaling components and
is more selective in inhibiting a subset of15% of TLR-inducible
genes, including those that encode MMPs (Hu et al., 2007). For
TLRs, the inhibitory effects of IFN-g are achieved by superinduc-
tion of transcriptional repressors, such as ATF-3. IFN-g and TLR
signaling synergistically induces expression of ATF-3 that binds
to and inhibits theMMP1 promoter (Ho et al., 2008). In addition,
IFN-g also inhibits AP-1 transcription factors that are required for
MMP expression (Ho et al., 2008). This inhibition of AP-1 and
downstream target genes is reminiscent of the above-discussed
findings that IFN-g inhibits IL-10 expression in part by inhibiting
AP-1 (Hu et al., 2006). IFN-g can transiently activate AP-1 in
certain cell types (Gough et al., 2007), but priming with IFN-g
suppresses AP-1 activity by several mechanisms, including
attenuation of upstreamMAPK pathways that induce expression
and increase transcriptional activity of AP-1 proteins (Hu et al.,
2006), suppression of transcription of genes encoding AP-1
components (Hu et al., 2006), downregulation of AP-1 mRNA
at the posttranscriptional level (Radzioch and Varesio, 1991),
and regulation of AP-1 protein stability (Hu et al., 2007). Destabi-
lization of the AP-1 protein c-Jun by IFN-g appears to be medi-
ated by GSK3, which phosphorylates c-Jun and creates a
binding site for the E3 ubiquitin ligase Fbw7 (Wei et al., 2005).
Overall, differential regulation of transcription factors down-
stream of TLR signaling by IFN-g (inhibiting AP-1 versus
Immunity
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Associated with IFN-g-Mediated
Attenuation of Tissue Destruction
IFN-g suppresses inflammatory tissue destruction
via regulation of IL-1R and TLR signaling. IFN-g
inhibits IL-1 signaling and subsequent induction
of destructive factors in macrophages by downre-
gulating IL-1RI expression. In addition, IFN-g
blocks induction of MMP downstream of TLR
signaling by superinducing transcription repressor
ATF3 and inhibiting transcription activators CREB
and AP-1. IFN-g inhibits CREB activity by sup-
pressing its serine phosphorylation and inhibits
AP-1 by downregulating nuclear protein levels of
its subunits. IFN-g inhibits osteoclastogenesis
and bone resorption via regulation of RANK,
CSF-1R, and TREM2 signaling. In osteoclast
progenitor cells, IFN-g suppresses expression as
well as signal transduction of RANK, CSF-1R,
and TREM2, receptors critical for the process of
osteoclastogenesis. IFN-g also attenuates fibrosis
via inhibition of TGF-bR and IL-4R signaling. IFN-g
suppresses TGF-bR signaling by induction of
inhibitory SMAD (SMAD7) and by direct inhibition
of SMAD3 by STAT1. IFN-g inhibits IL-4R signaling
by induction of SOCS1.augmenting NF-kB) provides a means to augment inflammatory
cytokine production yet to limit expression of tissue destructive
factors such asMMPs. Amore universal mechanism of suppres-
sion that is independent of upstream signaling involves STAT1-
mediated sequestration of the coactivator CBP, which is then
not available to activate MMP gene promoters (Ma et al., 2005).
Another way by which IFN-g exerts homeostatic functions is
attenuation of tissue infiltration by neutrophils and monocytes.
In several models of human autoimmune disorders such as
experimental arthritis and EAE, deficiency of IFN-g signaling
results in increased accumulation of neutrophils and other
myeloid cells at sites of inflammation (Ferber et al., 1996; Irmler
et al., 2007; Manoury-Schwartz et al., 1997; Vermeire et al.,
1997). Several mechanisms may account for the suppressive
effects of IFN-g on inflammatory cell infiltration: (1) IFN-g atten-
uates myelopoiesis and granulopoiesis and thus limits avail-
ability of infiltrating cells at their source. Several reports have
shown that IFN-g-deficient mice undergo deregulated expan-
sion of macrophages and granulocytes during infections (Mat-
thys et al., 1999;Murray et al., 1998). (2) IFN-g inhibits expression
of chemokines that attract cells to inflammatory sites. One
example of such regulation is IFN-g-mediated inhibition of
expression of MCP-2, a major neutrophil chemoattractant in
mice (Kelchtermans et al., 2007). (3) IFN-g alters cellular respon-
siveness to chemokines. This phenomenon is exemplified by the
observation that IFN-g arrests monocyte migration and alters
cellular responses to CCL2 by modulating the activities of
signaling molecules Pyk2, Jnk, Rac, and Cdc42 and inhibiting
CCL2-induced activation of PAK kinase that regulates cytoskel-
eton rearrangement and cell polarization (Hu et al., 2008b).
Inflammation often leads to tissue remodeling and bone
resorption, processes that are subject to inhibition by IFN-g.
Bone resorption is mediated by myeloid lineage cells called
osteoclasts, and IFN-g is a potent inhibitor of osteoclastogene-
sis (Takahashi et al., 1986; Takayanagi et al., 2005). IFN-g sup-
presses osteoclastogenesis in vitro and in vivo by regulating
the expression and signaling by two key receptors required forosteoclast generation and differentiation, c-Fms (the receptor
for macrophage colony-stimulating factor [M-CSF], also termed
CSF-1) and receptor activator of nuclear factor-kB (RANK),
a member of the TNF receptor family that binds its cognate
ligand RANKL. IFN-g interferes with RANK signaling by sup-
pressing expression of RANK and by targeting the key adaptor
molecule TRAF6 for proteasome-mediated degradation, result-
ing in diminished activation of downstream signaling events
(Takayanagi et al., 2000) (Figure 3). Similar to IFN-g, a type I
IFN, IFN-b, also inhibits RANK signaling in a STAT1-dependent
manner. However, instead of targeting TRAF6, IFN-b inhibits
translation of c-Fos, an AP-1 family transcription factor essential
for the induction of NFATc1, the master regulator of osteoclasto-
genesis (Takayanagi et al., 2002). Given that IFN-g suppresses
c-Fos expression in closely related cell types such as macro-
phages, it is possible that IFN-g targets c-Fos in osteoclasts in
addition to targeting RANK and TRAF6. One interesting possi-
bility awaiting assessment is the effect of IFN-g on CREB activa-
tion and function in the context of osteoclast differentiation.
Given the precedent of inhibition of TLR-induced CREB activity
by IFN-g in macrophages (Hu et al., 2006) and the critical role
of CREB in osteoclastogenesis (Sato et al., 2006), inhibition of
CREBmay contribute to IFN-g-mediated inhibition of osteoclas-
togenesis. IFN-g also inhibits expression of c-Fms, thus confer-
ring resistance to M-CSF stimulation (Baccarini et al., 1992;
Inaba et al., 1995) (Figure 3). DiminishedM-CSF responses result
in decreased production of osteoclast precursors and may also
explain the suppressive effects of IFN-g on myelopoiesis.
Fibrosis results fromaberrant tissue remodeling and excessive
connective tissue formation after injury or during chronic inflam-
mation. IFN-g suppresses fibrosis in several models including
viral hepatitis, bleomycin-induced pulmonary fibrosis, and
schistosomiasis-induced fibrosis (Wynn, 2004) at least in part
by inhibiting signaling by the major profibrotic factors IL-4,
IL-13, and TGF-b (Figure 3). These suppressive effects can be
mediated at least in part by the IFN-g-induced T-bet transcription
factor (Aliprantis et al., 2007). Alternatively activated or M2Immunity 31, October 16, 2009 ª2009 Elsevier Inc. 543
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ReviewFigure 4. Signaling Mechanisms
Associatedwith IFN-g-MediatedRegulation
of T Cell Differentiation and Function
In Th1 cell differentiation, IFN-g-STAT1 signaling is
critical for induction of T-bet and thus for
sustaining the positive feedback loop that leads
to heightened production of IFN-g. IFN-g blocks
Th2 cell differentiation by inhibiting IL-4-
STAT6 signaling. IFN-g and STAT1 also block
Th17 cell differentiation. IFN-g-STAT1 signaling
can potently inhibit Th17 cell differentiation, but
the mechanism of action is not clear. Because
STAT3 signaling from multiple cytokines including
IL-6, IL-23, and IL-21 plays a pivotal role in medi-
ating Th17 cell differentiation, it is possible that
IFN-g-STAT1 suppresses Th17 cell by targeting
STAT3 (as shown by dotted lines). IFN-g and
STAT1 also inhibit the aryl hydrocarbon nuclear
receptor (AHR) important for Th17 cell differentia-
tion, and it is possible that suppression of TGF-b
and IL-1 signaling by IFN-g contributes to inhibi-
tion of Th17 cell differentiation (not depicted).
IFN-g further regulates Treg cell differentiation
and function. IFN-g can block TGFb-mediated
Treg cell differentiation. In Foxp3+ Treg cells, IFN-g upregulates expression of T-bet, which in turns promotes expression of CXCR3 that regulates homing of
T-bet+ FoxP3+ Treg cells to sites of Th1 cell inflammation. T-bet also increases suppressive function of Treg cells, and T-bet+ FoxP3+ Treg cells effectively
suppress Th1 cell inflammation in vivo.macrophages havebeenproposed toplay a key role inpromoting
fibrosis (Mosser and Edwards, 2008; Wynn, 2004), and IFN-g-
mediated diversion of macrophage differentiation away from a
wound-healing profibrotic M2 phenotype also probably contrib-
utes to suppression of fibrosis. In addition to its effects on
fibrosis, IFN-g-mediated modulation of the balance between
M1 and M2 macrophage differentiation also contributes to other
important processes such as host defense, immune regulation,
and tissue remodeling (Mosser and Edwards, 2008). Finally,
IFN-g suppresses fibrosis by inhibiting collagen synthesis.
In summary, IFN-g attenuates tissue destruction by modu-
lating the expression, signaling, and function of tissue-destruc-
tive cytokines and their receptors, with resulting suppression
of gene expression and of cell recruitment and differentiation.
Where studied, these suppressive effects are dependent on
STAT1, suggesting indirect regulation mediated by STAT1 target
genes such as ATF3. Identification and characterization of
STAT1 target genes that regulate tissue-destructive pathways
represents a fruitful area for future research.
Regulation of Adaptive Immunity: Th and Treg Cell
Differentiation
As amajor effector cytokine of Th1 cell immunity, it is no surprise
that IFN-g autoamplifies Th1 cell responses (Figure 4) and cross-
inhibits differentiation and function of other Th cell subsets
including Th2 and Th17 cells. This regulation by IFN-g represents
a mechanism for maintaining Th1 cell lineage commitment and
stabilizing Th cell phenotypes (Szabo et al., 2003). One general
theme underlying IFN-g-mediated cross-inhibition is interfer-
ence with signal transduction pathways and transcription factors
downstream of cytokines that drive differentiation of other Th cell
subtypes. For example, IFN-g suppresses the IL-4-STAT6
pathway that is required for Th2 cell differentiation, mediated in
part by induction of SOCS1 that inhibits IL-4 receptor signaling
(Naka et al., 2001; Yu et al., 2004) (Figure 4). In addition, IFN-g-
induced T-bet suppresses Th2 cell differentiation by inhibiting544 Immunity 31, October 16, 2009 ª2009 Elsevier Inc.the expression and/or function of the Th2 cell transcription
factor GATA3 (Hwang et al., 2005; Yu et al., 2004). Another
SOCS-independent inhibitory mechanism is posttranscriptional
downregulation of IL-4-induced IL-4R gene expression (So
et al., 2000).
DifferentiationofTh17cells,which isdrivenby IL-6, IL-1, TGF-b,
IL-21, and IL-23 (Zhou et al., 2009), is strongly suppressed by
IFN-g in vitro and in vivo. In vitro, treatmentwith IFN-gneutralizing
antibody during the course of Th17 cell differentiation leads to
increased frequency of Th17 cells, whereas exogenous IFN-g
reduces the Th17 cell population (Harrington et al., 2005). In vivo,
IFN-g deficient mice exhibit enhanced Th17 cell responses in
several disease models including mycobacterial infection and
collagen-induced arthritis (Chu et al., 2007; Cruz et al., 2006; Irm-
ler et al., 2007). Aside from its effects on Th17 cell development, it
was recently reported that IFN-g inhibits effector functions of
Th17 cells (Kelchtermans et al., 2009). Although cross-inhibition
of Th17 cell development by IFN-g is relatively well established,
the mechanisms are not clear. Inhibition by IFN-g is likely to be
dependent on STAT1, given that STAT1-deficient mice mount
enhanced Th17 cell responses, and another STAT1-activating
cytokine, IL-27, potently suppresses Th17 cell development in
a STAT1-dependent manner (Stumhofer et al., 2006). The mole-
cules that are important for Th17 cell differentiation and that
are inhibited by IFN-g have not been unequivocally identified.
Possibilities include inhibition of Smad signaling downstream of
TGF-b (Tanaka et al., 2008), downregulation of T cell IL-1R
expression (X.H., unpublished data), and inhibition of the aryl
hydrocarbon receptor (Kimura et al., 2008). In addition, STAT1
inhibits STAT3 (see below), which is activated by IL-6, IL-23,
and IL-21 and is important for Th17 cell differentiation; it is
possible that STAT1 suppresses Th17 cell differentiation by
targeting STAT3 (Figure 4).
Th17 cell responses are important for host defense against
extracellular bacteria and yeast and are characterized by neutro-
phil infiltration and the potential for severe tissue destruction
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differentiation by IFN-g may represent an important pathway to
limit tissue inflammation and damage. Emerging evidence
suggests a greater complexity in IFN-g-mediated regulation of
Th17 cells than previously appreciated. Many Th cells at sites
of inflammation, such as the central nervous system in EAE,
coexpress IFN-g and IL-17, and recent evidence supports
plasticity in the Th17 cell lineage, with the potential to evolve
into IFN-g-expressing cells (Lee et al., 2009). Thus, different
from Th1 and Th2 cells, the relationship of Th1 and Th17 cells
is not limited to cross-inhibition. Instead, there is a potential for
ongoing generation and differentiation of Th cells with a changing
or mixed effector phenotype. This allows fine tuning of Th1-Th17
cell effector functions to achieve the most effective host
response during the course of infections and to balance immu-
nity with preservation of tissue integrity.
Regulatory T (Treg) cells serve to restrain overactivation of
effector T cells and maintain homeostasis. Interest in the role
of IFN-g in Treg cell development was prompted by the initially
paradoxical findings that IFN-g is protective inmodels of autoim-
mune diseases such as EAE (Ferber et al., 1996; Willenborg
et al., 1996). Exacerbation of EAE in mice deficient in IFN-g
signaling correlates with reduced numbers and function of
Treg cells (Nishibori et al., 2004; Wang et al., 2006). Moreover,
adoptive transfer of IFN-g-treated Treg cells is sufficient to
ameliorate EAE symptoms (Nishibori et al., 2004), supporting
an essential role of IFN-g in Treg cell development, at least in
EAEmodel. However, it is difficult to reconcile the above findings
with the observations that Treg cell development proceeds nor-
mally in the absence of IFN-g signaling under many conditions
(Kelchtermans et al., 2005). Recently, the emerging concept of
Treg cell diversity and polarization has shed light on the contro-
versial issue of the involvement of IFN-g in Treg cell development
(Barnes and Powrie, 2009). Two elegant studies suggest that,
similar to effector T cells, Treg cells undergo polarization into
specialized phenotypes and that factors important for effector
T cell development may also play a critical role in Treg cell polar-
ization (Koch et al., 2009; Zheng et al., 2009). For example, IRF4,
a transcription factor key for differentiation of Th2 cells, is
required for differentiation and function of a Treg cell subset
that specifically suppresses Th2 cell responses (Zheng et al.,
2009). In parallel, T-bet, a master regulator of Th1 cell differenti-
ation, is upregulated by IFN-g-STAT1 signaling in Foxp3+ Treg
cells, and Foxp3+T-bet+ cells represent a novel subset of Treg
cells that selectively dampens Th1 cell responses (Koch et al.,
2009) (Figure 4). The existence of specialized Treg cell subsets
may help to explain the apparent discrepancy that IFN-g is
necessary for Treg cell development under certain circum-
stances but not under others. Interestingly, as a major effector
of Th1 cell responses, IFN-g promotes differentiation of
Foxp3+T-bet+ Treg cells that suppress Th1 cell responses, and
such a differentiation constitutes a negative feedback loop that
contributes to homeostatic action of IFN-g. Overall, recent
developments implicate a regulatory role of IFN-g in modulating
many aspects of T cell biology aside from its classic activating
role in Th1 cell responses. In addition to its action on T cells,
IFN-g suppresses early B cell development in the bone marrow
and also promotes isotype switching to IgG2a, underscoring
its diverse effects on adaptive immunity (Schroder et al., 2004).Cross-inhibition of the Opposing STATs
Mechanisms by which IFN-g and STAT1 regulate the function
of receptors that activate distinct signaling pathways were
described above. In this section, we will review mechanisms
by which IFN-g and STAT1 regulate signaling by cytokines that
utilize the Jak-STAT pathway but have different and opposite
functions from IFN-g. Cytokines that oppose each other often
activate different STATs that antagonize each other. A good
example of antagonistic STATs is STAT1 and STAT3, which
are activated by the opposing cytokines IFN-g and IL-10,
respectively. STAT1 and STAT3 oppose each other in many
biological processes including macrophage activation that is
enhanced by STAT1 and inhibited by STAT3, cell proliferation
that is suppressed by STAT1 and promoted by STAT3, and Th
cell differentiation in which STAT1 promotes Th1 cell responses
and STAT3 drives Th17 cell responses (O’Shea and Murray,
2008).
The best-establishedmechanismbywhich STATs oppose one
another is indirect regulation mediated by SOCS proteins that
suppress signaling by cytokine receptors by inhibiting
receptor-associated Jaks, binding to and blocking STAT dock-
ing sites, and targeting receptors for proteosomal degradation
(Yoshimura et al., 2007). IFN-g and STAT1 activate expression
of SOCS1, a potent feedback inhibitor of IFN-g signaling that
also cross-inhibits signaling by the type I IFN receptor and the
IL-4 receptor (Dickensheets et al., 1999; Fenner et al., 2006;
Losman et al., 1999; Naka et al., 2001; Yu et al., 2004; Zimmerer
et al., 2007). Thus, SOCS1-mediated inhibition can explain
the suppressive properties of IFN-g on Th2 cell differentiation
(Figure 4). However, SOCS1 does not effectively inhibit signaling
by the IL-10 receptor or IL-6-related receptors that utilize gp130
and is not known to inhibit signaling by IL-21 or IL-23. Thus, IFN-
g-mediated antagonism of IL-10 function (Herrero et al., 2003;
Lauw et al., 2000; Pajkrt et al., 1997) can not be explained by
a SOCS1-dependent mechanism; it also appears likely that
regulation of Th17 cell differentiation by IFN-g can not be
explained solely by induction of SOCS1 or other SOCS proteins.
STAT1 also suppresses STAT3 by alternative and more direct
mechanisms, as was first suggested by genetic evidence
showing increased STAT3 activation in STAT1-deficient cells
(Gil et al., 2001; Qing and Stark, 2004; Ramana et al., 2001).
Mechanisms by which STAT1 can potentially directly inhibit
STAT3 include competition for binding to docking sites on recep-
tors or to target DNA sequences in promoters, competition for
binding to other proteins or cofactors, sequestration of STAT3
from active complexes, and direct transcriptional repression of
STAT3 target genes. These mechanisms are relevant not only
for cross-inhibition of signaling by other cytokines but also for
establishing the balance of STAT activation downstream of the
IFNGR. Ligation of IFNGR leads to activation of both STAT1
and STAT3. However, in most cells STAT3 activity is kept low
because of cross-inhibition by STAT1. Thus, the contribution of
STAT3 to IFN-g function is limited in most contexts and is best
revealed in cells deficient in STAT1 (Gil et al., 2001; Qing and
Stark, 2004). STAT1 suppresses IFNGR-mediated activation of
STAT3, at least in part by competing for the STAT docking site
within the IFNGR cytoplasmic domain. Because receptor dock-
ing is a prerequisite for activation by tyrosine phosphorylation,
the prediction of the competition for docking sites model isImmunity 31, October 16, 2009 ª2009 Elsevier Inc. 545
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stream of IFNGR or other receptors. Several reports using cell
lines support this model (Costa-Pereira et al., 2002; Qing and
Stark, 2004), but suppression of STAT3 tyrosine phosphorylation
by STAT1 appears to be context dependent, and in primary
macrophages it is clear that IFN-g and STAT1 suppress STAT3
function without suppressing its tyrosine phosphorylation (Her-
rero et al., 2003). Conceivably, STAT1 could suppress STAT3
function by displacing STAT3 from binding at target gene
promoters; in the case of promoter binding by the STAT1b iso-
form that does not contain a transcription activation domain,
such binding would lead to inhibition of transcription. There is,
however, very limited evidence to support mechanisms that
involve competition for binding to target DNA elements or for
transcriptional coactivators.
An alternative explanation for how STAT1 can inhibit STAT3
function without suppressing STAT3 tyrosine phosphorylation
is sequestration of STAT3 away from active complexes into
STAT1:STAT3 heterodimers. This will result in diminished
amounts of STAT3:STAT3 homodimers, such as those activated
by IL-10, that are transcriptionally active and functional. It is
possible that STAT1:STAT3 heterodimers are less transcription-
ally active than STAT3 homodimers or bind to alternative
promoters. Sequestration of STAT3 into STAT1:STAT3 hetero-
dimers is increased in cells that have been primed and that
express increased amounts of STAT1; near complete sequestra-
tion of STAT3 into STAT1:STAT3 heterodimers in primed cells
correlates with diminished STAT3 function (Herrero et al.,
2003). Under these conditions of dimerization with excess
STAT1, STAT3 can be retained in the cytoplasm, with diminished
target gene expression secondary to decreased nuclear translo-
cation (Hu et al., 2005b). In addition to suppressing STAT3
homodimer formation, incorporation of STAT3 into STAT1:
STAT3 heterodimers can result in diminished formation of other
active STAT3-containing complexes, such as STAT3-Jun
complexes important for activation of specific target genes
(Ivanov et al., 2001). Interestingly, this sequestration model by
which STAT1 inhibits transcription factors extends to inhibition
of RUNX2 and NF-kB by STAT1 binding and subsequent trap-
ping of these transcription factors in the cytoplasm (Kim et al.,
2003; Kramer et al., 2006). Finally, it is possible that STAT1 can
bind to STAT3 target genes and directly suppress transcription
by recruiting transcriptional repressors. An interesting area for
future investigation will be to determine whether STAT1 can
indeed directly repress gene transcription, in contrast to the
indirect mechanisms that have been described previously and
reviewed here. It will also be important to determinemechanisms
by which IFN-g and STAT1 inhibit STAT3-mediated IL-6, IL-21,
and IL-23 function during Th17 cell differentiation.
Role in Autoimmune Diseases
Autoimmune diseases are characterized by the development of
autoimmunity against self-antigens, together with an effector
phase characterized by chronic inflammation and attendant
tissue damage. Many autoimmune diseases, such as rheuma-
toid arthritis (RA), multiple sclerosis (MS), inflammatory bowel
disease, psoriasis, and lupus nephritis, are characterized by
the presence of activated macrophages at sites of inflammation
and disease. These macrophages exhibit an ‘‘M1’’ classically546 Immunity 31, October 16, 2009 ª2009 Elsevier Inc.activated phenotype and are believed to be key players in path-
ogenesis via production of cytokines such as TNF, IL-1, and IL-6
(Mosser and Edwards, 2008). Thus, on the basis of its macro-
phage-activating properties, IFN-g has been considered an
attractive candidate pathogenic cytokine in autoimmune
diseases. Several mouse models of autoimmune diseases,
such as collagen-induced arthritis (CIA) and EAE, were originally
thought to be predominantly Th1 cell mediated, further support-
ing the notion that IFN-g is pathogenic. However, consistent with
the pleiotropic activating and suppressive functions of IFN-g
described above, it is now clear that IFN-g has both promoting
and suppressive effects in autoimmune diseases. Most strik-
ingly, IFN-g suppresses Th17 cell-mediated autoimmunity in
mice and can have both augmenting and suppressive effects
on autoimmunity and on the effector inflammatory phase of auto-
immune diseases (Kelchtermans et al., 2008), depending on the
specific disease and the timing, location, and intensity of IFN-g
action.
It is now clear on the basis of genetic evidence that EAE and
CIA are Th17 cell-mediated disease models. In EAE, genetic
ablation of IFN-g or the IFNGR results in increased morbidity
and mortality (Ferber et al., 1996; Willenborg et al., 1996). Exac-
erbated disease in the absence of IFN-g signaling is associated
with massive central nervous system infiltrates composed of
neutrophils and macrophages (Ferber et al., 1996; Willenborg
et al., 1996). In CIA, deficiency of IFNGR leads to accelerated
onset and increased incidence of disease (Manoury-Schwartz
et al., 1997; Vermeire et al., 1997). Joint lesions of IFNGR defi-
cient mice in CIA are characterized by increased infiltration of
neutrophils and macrophages, with increased tissue destruction
and bone erosion (Manoury-Schwartz et al., 1997; Vermeire
et al., 1997). In both EAE and CIA, the protective role of IFN-g
has been attributed to its suppression of Th17 cell responses,
and this notion is supported by evidence that IL-17 antibodies
attenuate arthritis in IFN-g-deficient animals in two different
models (Chu et al., 2007; Kelchtermans et al., 2009). However,
as discussed above, attenuation of disease by IFN-g is also
probably mediated by additional protective mechanisms such
as suppression of production of chemokines, cytokines, and
tissue-destructive enzymes (Guedez et al., 2001; Kelchtermans
et al., 2007; Willenborg et al., 1999), infiltration of inflammatory
cells, and differentiation of osteoclasts; modulation of Treg cell
function may also be important and IFN-g-induced Treg cell
subsets may specifically attenuate Th1cell-mediated pathology
while allowing Th17 cell-mediated pathology to progress. Finally,
strong activation of the IL-12-IFN-g axis leads to enhanced IL-10
production by Th1 cells, which constitutes another feedback
loop that can attenuate disease pathology (Saraiva et al., 2009).
Although IFN-g is clearly protective in EAE and CIA, it is overly
simplistic to conclude that IFN-gplaysaprotective role inmultiple
sclerosis and rheumatoid arthritis on the basis of its role in these
two acute neutrophil-dominated models of chronic human
autoimmune diseases that exhibit a more complex and often
different pathology. Indeed, administration of IFN-g induces
exacerbations of MS in humans (Panitch et al., 1987), and IFN-
g is pathogenic in other models of RA, such as proteoglycan-
induced arthritis, and in CIA when complete Freund’s adjuvant
(CFA) is not used during disease induction (Finnegan et al.,
2002; Matthys et al., 1999). Even in CIA induced with standard
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disease depending on whether it is provided locally or systemi-
cally and on timing of administration (Boissier et al., 1995).
More recent work (Kroenke et al., 2008; Luger et al., 2008; Stein-
man, 2008) supports the fact that both Th1 and Th17 cells can
contribute to pathogenesis of EAE and experimental allergic
uveitis (EAU). The predominant pathogenic Th cell type is deter-
mined by the methods used to induce disease, especially by
the use of adjuvants such as CFA that contain various TLR
ligands. Th17 cell-mediated disease was characterized by
neutrophil-rich infiltrates. In contrast, Th1 cell disease had
predominantmacrophage infiltrates,which ismorecharacteristic
ofMS,RA, andmany humanautoimmune diseases. Thus, amore
balanced role for Th1 cells and IFN-g in autoimmune diseases is
emerging, with a mixed picture in which Th1 and Th17 cells can
coexist and contribute to pathology. Thismixed picture is consis-
tent with lineage plasticity and coexpression of IFN-g and IL-17
by certain Th cells as discussed above and is supported by
data showing coexpression of IFN-g and IL-17 in various models
anddiseases, includingRA, systemic lupuserythematosus (SLE),
EAE, Crohn’s disease, and psoriasis. One recent study shows
that IFN-g actually contributes to induction of Th17 cell migration
and differentiation in the context of psoriasis, suggesting that
IFN-g may play a positive role in Th17 cell responses (Kryczek
et al., 2008). Overall, a large body of work highlights the complex
interplay between Th1 cells-IFN-g and Th17 cells in vivo and
suggests that IFN-g could differentially regulate Th17 cell
responses under different disease conditions.
A pathogenic role of Th1 cells and IFN-g in autoimmune
diseases raises the question of mechanisms by which IFN-g
contributes to pathogenesis. Given the above discussion, a
good candidate mechanism is IFN-g-mediated activation of
macrophages and other cell types at sites of inflammation, and
thus augmentation of the effector inflammatory component of
autoimmune diseases. In this scenario, the activating and
priming functions of IFN-g that lead to increased inflammatory
cytokine production and abrogate homeostatic mechanisms
contribute to disease pathology. Indeed, we and others have
provided evidence supporting IFN-g-mediated priming of
macrophages in human RA andmousemodels of lupus nephritis
(Hu et al., 2002; Wang et al., 2008). In support of a role for IFN-g
in augmenting inflammation in autoimmune diseases, local
administration or tissue-specific transgene-mediated expres-
sion of IFN-g at inflammatory sites exacerbates disease in
arthritis and autoimmune diabetes models. Additional support
for a role for IFN-g in the effector phase of autoimmune disease
is provided by genetic evidence showing that deletion of the Ifng
gene ameliorates nephritis in the MRL/lpr model of SLE in which
nephritis is dependent on pathogenic macrophages (Baccala
et al., 2005). Importantly, autoimmunity did not appear to be
diminished in IFN-g-deficient animals, supporting the idea that
IFN-g can boost inflammation and tissue destruction in the
kidney independently of the autoimmune process. However,
there is also evidence that IFN-g can suppress the inflammatory
effector phase of autoimmunity. The clearest example may be
the increased severity of arthritis in IFN-g-deficient mice in the
K/BxN model that is induced by passive transfer of autoanti-
bodies and does not depend on acquired immunity (Wu et al.,
2007). Conversely, systemic administration of exogenous IFN-gsuppressed K/BxN arthritis. The mechanism by which IFN-g
suppresses K/BxN arthritis is inhibition of neutrophil infiltration
of joints, although it is possible that direct attenuation of tissue
destruction and osteoclastogenesis could also play a role.
The complex role of IFN-g in autoimmune diseases has impor-
tant therapeutic implications. A detailed understanding of key
pathogenic processes will be required to determine whether
blocking endogenous IFN-g or administering exogenous IFN-g
may be efficacious, and at which point in the disease process,
given that IFN-g may ameliorate or exacerbate disease under
different circumstances. It will be equally important to under-
stand the interplay between Th1 and Th17 cell responses in
specific autoimmune diseases. Blockade of solely IFN-g or
Th17 cell cytokines may result only in partial therapeutic efficacy
and a shift to a different pathology. In diseases in which Th1 and
Th17 cells work together, blocking both may be required for
effective therapy. Indeed, the striking beneficial effects of anti-
bodies against IL-12 p40 in diseases such as Crohn’s disease
and psoriasis may be explained by attenuation of both Th1 and
Th17 cell responses (Ghosh et al., 2006; Nestle et al., 2009). It
will be interesting to see the effects of IL-12 p40 blockade in
autoimmune diseases such as MS and RA.
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